Consensus nomenclature for CD8+ T cell phenotypes in cancer
Lionel Apetoh
,
Mark Smyth
,
Charles Drake
,
Pierre Abastado
,
Ron Apte
,
Maha Ayyoub
,
Jean-Yves Blay
,
Marc Bonneville
(1)
,
Lisa Butterfield
,
Anne Caignard
,
Chiara Castelli
,
Federica Cavallo
,
Esteban Celis
,
Lieping Chen
,
Mario Colombo
,
Begoña Comin-Anduix
,
Georges Coukos
,
Madhav V Dhodapkar
,
Glenn Dranoff
,
Ian Frazer
,
Wolf-Hervé Fridman
,
Dmitry I Gabrilovich
,
Eli Gilboa
,
Sacha Gnjatic
,
Dirk Jäger
,
Pawel Kalinski
,
Howard Kaufman
,
Rolf Kiessling
,
John Kirkwood
,
Alexander Knuth
,
Roland Liblau
,
Michael Lotze
,
Enrico Lugli
,
Francesco Marincola
,
Ignacio Melero
,
Cornelis Melief
,
Thorsten Mempel
,
Elizabeth A Mittendorf
,
Kunle Odun
,
Willem Overwijk
,
Anna Karolina Palucka
,
Giorgio Parmiani
,
Antoni A Ribas
,
Pedro Romero
,
Robert Schreiber
,
Gerold Schuler
,
Pramod K Srivastava
,
Eric Tartour
,
Danila Valmori
,
Sjoerd van Der Burg
,
Pierre van Der Bruggen
,
Benoît van den Eynde
,
Ena Wang
,
Weiping Zou
,
Theresa L Whiteside
,
Daniel E Speiser
,
Drew Pardoll
,
Nicholas P Restifo
,
Ana Anderson
Lionel Apetoh
- Function : Author
- PersonId : 996006
Mark Smyth
- Function : Author
Charles Drake
- Function : Author
Pierre Abastado
- Function : Author
Ron Apte
- Function : Author
Maha Ayyoub
- Function : Author
- PersonId : 773870
- ORCID : 0000-0003-2022-0898
Jean-Yves Blay
- Function : Author
- PersonId : 756201
- ORCID : 0000-0001-7190-120X
- IdRef : 069035407
Lisa Butterfield
- Function : Author
- PersonId : 899092
Anne Caignard
- Function : Author
- PersonId : 180979
- IdHAL : acaignard
- ORCID : 0000-0001-9923-6045
- IdRef : 070306680
Chiara Castelli
- Function : Author
Federica Cavallo
- Function : Author
Esteban Celis
- Function : Author
Lieping Chen
- Function : Author
Mario Colombo
- Function : Author
Begoña Comin-Anduix
- Function : Author
Georges Coukos
- Function : Author
Madhav V Dhodapkar
- Function : Author
Glenn Dranoff
- Function : Author
- PersonId : 924474
Ian Frazer
- Function : Author
Wolf-Hervé Fridman
- Function : Author
Dmitry I Gabrilovich
- Function : Author
Eli Gilboa
- Function : Author
Sacha Gnjatic
- Function : Author
Dirk Jäger
- Function : Author
Pawel Kalinski
- Function : Author
- PersonId : 924491
Howard Kaufman
- Function : Author
- PersonId : 942526
Rolf Kiessling
- Function : Author
- PersonId : 924495
John Kirkwood
- Function : Author
- PersonId : 899112
Alexander Knuth
- Function : Author
Roland Liblau
- Function : Author
- PersonId : 1033157
- ORCID : 0000-0001-5477-5475
- IdRef : 076944263
Michael Lotze
- Function : Author
- PersonId : 899116
Enrico Lugli
- Function : Author
Francesco Marincola
- Function : Author
- PersonId : 938464
Ignacio Melero
- Function : Author
Cornelis Melief
- Function : Author
Thorsten Mempel
- Function : Author
Elizabeth A Mittendorf
- Function : Author
Kunle Odun
- Function : Author
Willem Overwijk
- Function : Author
Anna Karolina Palucka
- Function : Author
Giorgio Parmiani
- Function : Author
- PersonId : 924513
Antoni A Ribas
- Function : Author
Pedro Romero
- Function : Author
- PersonId : 760024
- ORCID : 0000-0001-9947-3868
Robert Schreiber
- Function : Author
Gerold Schuler
- Function : Author
Pramod K Srivastava
- Function : Author
Eric Tartour
- Function : Author
- PersonId : 762312
- ORCID : 0000-0002-7323-468X
- IdRef : 076543234
Danila Valmori
- Function : Author
Sjoerd van Der Burg
- Function : Author
- PersonId : 924528
Pierre van Der Bruggen
- Function : Author
Benoît van den Eynde
- Function : Author
Ena Wang
- Function : Author
- PersonId : 899091
Weiping Zou
- Function : Author
- PersonId : 766729
- ORCID : 0000-0001-7952-3549
Theresa L Whiteside
- Function : Author
Daniel E Speiser
- Function : Author
Drew Pardoll
- Function : Author
Nicholas P Restifo
- Function : Author
Ana Anderson
- Function : Author
Abstract
Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.